Injury recovery and the Wolverine stack

BPC-157 and TB-500 attract people hoping for less pain, easier movement and a return to training. Neither has been shown to be the better human injury treatment.

The useful differences are the product, the route and the extra uncertainty from combining them. ‘Local versus whole-body healing’ is too simple a rule.

Compare reported amounts Does stacking help?

Two names, overlapping goals

BPC-157

Often sought for a stubborn injury or gut symptoms.

TB-500

Often added for wider recovery and mobility goals.

Does adding both help more?

An extra human recovery benefit has not been established.

Compare movement, strength and return to activity—not just the number of ingredients.

Side by side

What recovery users are comparing

Compare BPC-157TB-500
What people seek Relief from a stubborn tendon or ligament problem; also discussed for gut symptoms Easier movement and broader muscle or tendon recovery, often alongside BPC-157
What remains unanswered Whether it reliably heals a human injury or shortens rehabilitation Whether it improves human recovery or adds benefit to BPC-157
Important product distinction Capsules, under-skin injections and joint injections are different routes A short TB-500 fragment and full thymosin beta-4 are different molecules
These are reported goals and practical differences, not an injury-by-injury treatment ranking.

Reported amounts, frequency and course length

The following are two separate examples, not a combined schedule. The BPC brochure specifies under-skin injection. The TB-500 example mentions under-skin use, without establishing the route for the whole course. Neither report establishes that the regimen is effective or safe.

Two reported courses—not a stack prescription

Compare BPC-157: clinic brochureTB-500 name: one self-report
Amount 250–500 mcg total per day 2.5 mg per injection
How often Daily Twice weekly in weeks 1–4; once weekly in weeks 5–13
How long 4–6 weeks; the brochure then lists a 4-week break 13 weeks in this personal report
The BPC-157 amount is a daily total. The TB-500 amount is per injection, and that person's product sequence was not verified. Neither course is a healing deadline.

The BPC-157 figures come together from the House of Gaia brochure’s BPC entry; the TB-500 figures belong to one self-reported course, not a studied regimen. The latter represents 5 mg/week initially and 2.5 mg/week afterward. These examples explain why daily versus weekly numbers look different; they do not prove which frequency is better. The provider example was checked in the earlier dose review; it does not establish clinical benefit.

Do not turn the two rows into a new “standard stack,” convert them into oral doses, or copy a syringe-unit number without the exact concentration. Loading, maintenance and time off are features of particular reports—not established requirements for tissue repair.

Is BPC-157 local and TB-500 systemic?

That shortcut is not a reliable way to choose between them. BPC-157 has laboratory and animal repair research, but changes in repair-related cell signals do not show that an under-skin injection preferentially treats the nearest tendon. There is no dependable human comparison establishing that injecting near an injury works better. Tendon-cell experiment, FDA BPC-157 review.

For TB-500, first check which molecule is being discussed. FDA’s review identifies TB-500 as the short N-acetyl-LKKTETQ fragment, while full thymosin beta-4 has 43 amino acids. Commercial naming is inconsistent. The parent molecule’s roles in cell movement and repair do not establish whole-body recovery from the fragment, or mean one is equivalent to the other. FDA TB-500 review.

What human studies do—and do not—show

A small clinic report found pain improvement in some people receiving BPC-157 injections into the knee. Sixteen patients were reached by telephone: twelve had BPC-157 alone and four had BPC-157 plus a preparation described as TB4. It was not randomized and did not confirm structural healing with follow-up imaging. Four combination reports cannot establish that adding TB4 works better—or that a product sold as TB-500 has the same effect. Original knee-pain report.

Full-length thymosin beta-4 has also been studied intravenously in healthy volunteers. That safety/PK study did not test injured tendons or the short fragment. It cannot supply a human TB-500 recovery result. Original IV study.

The “Wolverine stack” and reported protocols

“Wolverine stack” usually means BPC-157 plus a product called TB-500. People combine them hoping for complementary recovery effects. That rationale has not established an added human benefit. A fixed-ratio blend also means changing the amount changes both ingredients, making it harder to separate their effects or unwanted reactions.

A 2026 rat Achilles-tendon study compared BPC-157, a product called TB-500, both together and a control. The combination showed no added benefit under those conditions. The TB-500 arm had a tendon-strength improvement against control, but that is not a human superiority result. The paper names a supplier product without specifying its peptide sequence, so it should not be treated as confirmed evidence for the short fragment. Original study.

Side effects and practical trade-offs

There is not enough reliable human information to rank one as safer or give dependable side-effect rates. FDA’s reviews raise concerns about immune reactions, peptide impurities and incomplete safety information for the injected products. BPC-157 review, TB-500 review.

A second peptide adds expense and another uncertain exposure. A purity percentage does not establish sterility, and a favorable short-term experience does not settle long-term safety. Symptoms, strength, movement and tolerance of rehabilitation load matter when judging recovery; less pain alone is not clearance to resume full training. Return-to-sport consensus.

How to read their curves

The plotter can illustrate how assumed doses overlap. It cannot show which peptide will heal an injury, where it acts, or whether a higher peak produces a better result. In particular, full-length thymosin beta-4 timing must not be assigned to its fragment.

For product-specific context, see the BPC-157 compound page and TB-500 compound page, or the longer BPC-157 and TB-500 guides.

Frequently asked questions

Which is better for a tendon injury: BPC-157 or TB-500?

There is no dependable human head-to-head result identifying a winner. BPC-157 has animal tendon-repair research and small human reports, while the TB-500 name creates additional uncertainty about the molecule. A local-versus-systemic label does not resolve the choice.

Does the Wolverine stack work better than one peptide?

An added human recovery benefit has not been established. The small knee-pain combination report was uncontrolled, and a 2026 rat experiment found no added combination benefit under its conditions. Neither supplies a validated human stacking schedule.

Is TB-500 supposed to be daily or twice weekly?

Published reports differ, and product identity is often unclear. The self-reported example here used twice-weekly injections initially, then weekly. That is one reported course, not an optimized frequency or a dose for a verified peptide sequence.

Are BPC-157 and TB-500 prohibited in sport?

Yes. WADA’s 2026 list names BPC-157 under S0 and thymosin-beta-4 and its derivatives, including TB-500, under S2. Both are prohibited in and out of competition.

Does pharmacy availability mean a product is approved?

No. Compounding-policy decisions are separate from approval of a finished medicine for a specific indication. A product name or reported protocol does not establish clinical benefit or safety.

Sources and scope